These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
375 related articles for article (PubMed ID: 18077994)
1. Liposomal doxorubicin in combination with bortezomib for relapsed or refractory multiple myeloma. Ning YM; He K; Dagher R; Sridhara R; Farrell AT; Justice R; Pazdur R Oncology (Williston Park); 2007 Nov; 21(12):1503-8; discussion 1511, 1513, 1516 passim. PubMed ID: 18077994 [TBL] [Abstract][Full Text] [Related]
2. United States Food and Drug Administration approval summary: bortezomib for the treatment of progressive multiple myeloma after one prior therapy. Kane RC; Farrell AT; Sridhara R; Pazdur R Clin Cancer Res; 2006 May; 12(10):2955-60. PubMed ID: 16707588 [TBL] [Abstract][Full Text] [Related]
3. Combined pegylated liposomal doxorubicin and bortezomib is highly effective in patients with recurrent or refractory multiple myeloma who received prior thalidomide/lenalidomide therapy. Sonneveld P; Hajek R; Nagler A; Spencer A; Bladé J; Robak T; Zhuang SH; Harousseau JL; Orlowski RZ; Cancer; 2008 Apr; 112(7):1529-37. PubMed ID: 18300257 [TBL] [Abstract][Full Text] [Related]
4. Randomized phase III study of pegylated liposomal doxorubicin plus bortezomib compared with bortezomib alone in relapsed or refractory multiple myeloma: combination therapy improves time to progression. Orlowski RZ; Nagler A; Sonneveld P; Bladé J; Hajek R; Spencer A; San Miguel J; Robak T; Dmoszynska A; Horvath N; Spicka I; Sutherland HJ; Suvorov AN; Zhuang SH; Parekh T; Xiu L; Yuan Z; Rackoff W; Harousseau JL J Clin Oncol; 2007 Sep; 25(25):3892-901. PubMed ID: 17679727 [TBL] [Abstract][Full Text] [Related]
5. Results from AMBER, a randomized phase 2 study of bevacizumab and bortezomib versus bortezomib in relapsed or refractory multiple myeloma. White D; Kassim A; Bhaskar B; Yi J; Wamstad K; Paton VE Cancer; 2013 Jan; 119(2):339-47. PubMed ID: 22811009 [TBL] [Abstract][Full Text] [Related]
6. A prospective, international phase 2 study of bortezomib retreatment in patients with relapsed multiple myeloma. Petrucci MT; Giraldo P; Corradini P; Teixeira A; Dimopoulos MA; Blau IW; Drach J; Angermund R; Allietta N; Broer E; Mitchell V; Bladé J Br J Haematol; 2013 Mar; 160(5):649-59. PubMed ID: 23293914 [TBL] [Abstract][Full Text] [Related]
7. Pegylated liposomal Doxorubicin: a review of its use in the treatment of relapsed or refractory multiple myeloma. Plosker GL Drugs; 2008; 68(17):2535-51. PubMed ID: 19016577 [TBL] [Abstract][Full Text] [Related]
8. A modified regimen of pegylated liposomal doxorubicin, bortezomib, and dexamethasone is effective and well tolerated in the treatment of relapsed or refractory multiple myeloma. Waterman GN; Yellin O; Swift RA; Mapes R; Eades B; Ackerman E; Berenson JR Ann Hematol; 2011 Feb; 90(2):193-200. PubMed ID: 20809423 [TBL] [Abstract][Full Text] [Related]
9. Thalidomide, dexamethasone, Doxil and Velcade (ThaDD-V) followed by consolidation/maintenance therapy in patients with relapsed-refractory multiple myeloma. Offidani M; Corvatta L; Polloni C; Gentili S; Mele A; Rizzi R; Catarini M; Caraffa P; Samori A; Blasi N; Ferranti M; Malerba L; Brunori M; Leoni P Ann Hematol; 2011 Dec; 90(12):1449-56. PubMed ID: 21437586 [TBL] [Abstract][Full Text] [Related]
10. Salvage therapy with pegylated liposomal doxorubicin, bortezomib, cyclophosphamide, and dexamethasone in relapsed/refractory myeloma patients. Romano A; Chiarenza A; Conticello C; Cavalli M; Vetro C; Di Raimondo C; Cunsolo R; Palumbo GA; Di Raimondo F Eur J Haematol; 2014 Sep; 93(3):207-13. PubMed ID: 24673398 [TBL] [Abstract][Full Text] [Related]
11. Efficacy and safety of pegylated liposomal Doxorubicin in combination with bortezomib for multiple myeloma: effects of adverse prognostic factors on outcome. Bladé J; Sonneveld P; San Miguel JF; Sutherland HJ; Hajek R; Nagler A; Spencer A; Robak T; Lantz KC; Zhuang SH; Harousseau JL; Orlowski RZ; Clin Lymphoma Myeloma Leuk; 2011 Feb; 11(1):44-9. PubMed ID: 21454189 [TBL] [Abstract][Full Text] [Related]
12. Retreatment with bortezomib alone or in combination for patients with multiple myeloma following an initial response to bortezomib. Sood R; Carloss H; Kerr R; Lopez J; Lee M; Druck M; Walters IB; Noga SJ Am J Hematol; 2009 Oct; 84(10):657-60. PubMed ID: 19731393 [TBL] [Abstract][Full Text] [Related]
13. Randomized phase II study of bortezomib alone and bortezomib in combination with docetaxel in previously treated advanced non-small-cell lung cancer. Fanucchi MP; Fossella FV; Belt R; Natale R; Fidias P; Carbone DP; Govindan R; Raez LE; Robert F; Ribeiro M; Akerley W; Kelly K; Limentani SA; Crawford J; Reimers HJ; Axelrod R; Kashala O; Sheng S; Schiller JH J Clin Oncol; 2006 Nov; 24(31):5025-33. PubMed ID: 17075122 [TBL] [Abstract][Full Text] [Related]
14. Bortezomib in combination with conventional chemotherapeutic agents for multiple myeloma compared with bortezomib alone. Min CK; Lee MJ; Eom KS; Lee S; Lee JW; Min WS; Kim CC; Kim M; Lim J; Kim Y; Han K Jpn J Clin Oncol; 2007 Dec; 37(12):961-8. PubMed ID: 18156171 [TBL] [Abstract][Full Text] [Related]
15. Extended follow-up of outcome measures in multiple myeloma patients treated on a phase I study with bortezomib and pegylated liposomal doxorubicin. Biehn SE; Moore DT; Voorhees PM; Garcia RA; Lehman MJ; Dees EC; Orlowski RZ Ann Hematol; 2007 Mar; 86(3):211-6. PubMed ID: 17146676 [TBL] [Abstract][Full Text] [Related]
16. Bortezomib, doxorubicin, and dexamethasone combination therapy followed by thalidomide and dexamethasone consolidation as a salvage treatment for relapsed or refractory multiple myeloma: analysis of efficacy and safety. Lee SS; Suh C; Kim BS; Chung J; Joo YD; Ryoo HM; Do YR; Jin JY; Kang HJ; Lee GW; Lee MH; Shim H; Kim K; Yoon SS; Bang SM; Kim HY; Lee JJ; Park J; Lee DS; Lee JH; Ann Hematol; 2010 Sep; 89(9):905-12. PubMed ID: 20349060 [TBL] [Abstract][Full Text] [Related]
17. Cost-effectiveness of novel relapsed-refractory multiple myeloma therapies in Norway: lenalidomide plus dexamethasone vs bortezomib. Möller J; Nicklasson L; Murthy A J Med Econ; 2011; 14(6):690-7. PubMed ID: 21892856 [TBL] [Abstract][Full Text] [Related]
18. Safety and efficacy of bortezomib and melphalan combination in patients with relapsed or refractory multiple myeloma: updated results of a phase 1/2 study after longer follow-up. Berenson JR; Yang HH; Vescio RA; Nassir Y; Mapes R; Lee SP; Wilson J; Yellin O; Morrison B; Hilger J; Swift R Ann Hematol; 2008 Aug; 87(8):623-31. PubMed ID: 18463870 [TBL] [Abstract][Full Text] [Related]
19. [Bortezomib-based combination therapy for relapsed or refractory multiple myeloma]. Yuan ZG; Hou J; Wang DX; Fu WJ; Chen YB; Xi H Zhonghua Nei Ke Za Zhi; 2008 Feb; 47(2):102-6. PubMed ID: 18683793 [TBL] [Abstract][Full Text] [Related]
20. The addition of liposomal doxorubicin to bortezomib, thalidomide and dexamethasone significantly improves clinical outcome of advanced multiple myeloma. Ciolli S; Leoni F; Casini C; Breschi C; Santini V; Bosi A Br J Haematol; 2008 Jun; 141(6):814-9. PubMed ID: 18410447 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]